Quest Diagnostics Stock Slides Despite Mixed Trading Session for the Market
April 20, 2023
Trending News 🌥️
Despite a mixed trading session on Tuesday, Quest Diagnostics ($NYSE:DGX) Inc. saw its stock slide by 0.69%, closing at $142.10. This was in line with the lower closing of the S&P 500 index. Quest Diagnostics is a publicly traded company that provides diagnostic information services and technologies to healthcare providers, laboratories and businesses. They specialize in a range of clinical, genetic and genomic testing services, clinical trials and other laboratory services such as drug safety monitoring.
The company has consistently delivered strong financial results and has grown its revenue and profits over time. While Quest Diagnostics stock has declined slightly during Tuesday’s market session, it still remains one of the most attractive stocks in its sector as it is expected to continue to outpace its peers in the years to come.
Price History
The stock opened at $141.9 and closed at $143.6, a 1.0% increase from the prior closing price of $142.1. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Quest Diagnostics. More…
| Total Revenues | Net Income | Net Margin |
| 9.88k | 942 | 9.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Quest Diagnostics. More…
| Operations | Investing | Financing |
| 1.72k | -543 | -1.73k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Quest Diagnostics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 12.84k | 6.83k | 54.69 |
Key Ratios Snapshot
Some of the financial key ratios for Quest Diagnostics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 8.6% | 5.1% | 14.0% |
| FCF Margin | ROE | ROA |
| 13.3% | 14.3% | 6.7% |
Analysis
At GoodWhale, we have conducted an analysis of QUEST DIAGNOSTICS‘s wellbeing. Based on our Risk Rating, QUEST DIAGNOSTICS is a medium risk investment in terms of both financial and business aspects. We have identified three risk warnings in the company’s income sheet, balance sheet, and non-financial areas. To gain deeper insights into our findings, register with us to get a closer look. With GoodWhale, you can make informed decisions when investing in QUEST DIAGNOSTICS. More…
Peers
The competition among Quest Diagnostics Inc, Dr Lalchandani Labs Ltd, NeoGenomics Inc, and Shanghai Labway Clinical Laboratory Co Ltd is fierce. All four companies are vying for a piece of the pie in the diagnostic testing market. While Quest Diagnostics Inc is the largest of the four companies, the other three are not far behind. Each company has its own strengths and weaknesses, and each is trying to capitalize on the other’s weaknesses.
– Dr Lalchandani Labs Ltd ($BSE:541299)
Lalchandani Labs Ltd is a pharmaceutical company that manufactures and markets a range of prescription and over-the-counter drugs. The company has a market cap of 141.91M as of 2022 and a return on equity of 12.87%. The company’s products are sold in over 50 countries and its products are used by millions of people around the world. The company has a strong research and development team that is constantly innovating and developing new products. The company’s products are backed by a strong clinical research and manufacturing infrastructure.
– NeoGenomics Inc ($NASDAQ:NEO)
NeoGenomics Inc is a leading provider of cancer genetic testing and information services. The company has a market cap of 934.66M as of 2022 and a Return on Equity of -3.79%. NeoGenomics provides a full range of services including DNA sequencing, gene expression profiling, FISH testing, and Flow Cytometry. The company also offers a wide array of diagnostic tests including next generation sequencing, immunohistochemistry, and in situ hybridization. NeoGenomics serves a global customer base of oncologists, pathologists, pharmaceutical companies, and academic research centers.
– Shanghai Labway Clinical Laboratory Co Ltd ($SZSE:301060)
Shanghai Labway Clinical Laboratory Co Ltd is a clinical laboratory located in Shanghai, China. The company provides a range of laboratory services, including medical testing, tissue culture, and genetic testing. The company has a market cap of 9.31B as of 2022 and a Return on Equity of 27.69%. The company’s strong market position and financial performance are due to its focus on quality and customer service. The company has a well-established reputation in the industry and is known for its accurate and reliable results.
Summary
Quest Diagnostics Inc. has recently seen its share price dip 0.69%, closing at $142.10. This was despite a generally positive day for the broader stock market, with the S&P 500 ending in positive territory. Analysts are divided on the future prospects of Quest Diagnostics stock, with some predicting a rebound while others remain cautious. Investors should do their own research and assess the long-term outlook of the company to make an informed decision.
Related Posts
Recent Posts
